Universal tumor testing for MMR deficiency, either by MMR protein immunohistochemistry or microsatellite instability (MSI) measurement, is recommended for the screening of Lynch syndrome and potential responders to immunotherapy [4]. This evidence concerns the gene MRC1 and neoplasm.